Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

Trial Identifier: 19140B
Sponsor: H. Lundbeck A/S
Start Date: September 2021
Primary Completion Date: June 2024
Study Completion Date: June 2024
Condition: Migraine

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
JP Kyoto Shimojo-ku, JP, 680-8811
JP Mibu-machi, JP, 321-0293
JP Shizuoka-shi, JP, 420-0853
JP Toyota-shi, JP, 471-8513
JP, Ôsaka Osaka-Shi, Ôsaka, JP, 556-0017
JP, Hirosima Hiroshima-Shi Naka-Ku, Hirosima, JP, 730-0031
JP, Hukuoka Kasuga-Shi, Hukuoka, JP, 816-0802
JP, Hukuoka Kasuga-Shi, Hukuoka, JP, 816-0824
JP, Ibaraki Mito, Ibaraki, JP, 310-0015
JP, Iwate Morioka-Shi, Iwate, JP, 020-0023
JP, Kagosima Kagoshima-Shi, Kagosima, JP, 892-0842
JP, Kôti Kochi, Kôti, JP, 780-0051
JP, Miyagi Sendai-Shi Taihaku-Ku, Miyagi, JP, 982-0014
JP, Saitama Saitama-Shi, Saitama, JP, 338-8577
JP, Tokyo Edogawa-Ku, Tokyo, JP, 134-0085
JP, Tokyo Shibuya-Ku, Tokyo, JP, 151-0051
JP, Yamaguti Hofu-Shi, Yamaguti, JP, 747-0802